Bruker Corporation announced a majority investment in RECIPE Chemicals + Instruments GmbH on April 16, 2025. RECIPE, based in Munich, Germany, is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and clinical in vitro diagnostic kits.
RECIPE, a profitable company with over $15 million in revenues in 2024, will continue to operate under its current leadership. This acquisition immediately enhances Bruker's capabilities in small molecule clinical diagnostic assays, particularly with RECIPE’s ClinMASS® kits for Bruker’s EVOQ® liquid chromatography triple-quadrupole mass spectrometers.
The companies are also preparing to introduce high-throughput, chromatography-free ('chrom-free') RECIPE ClinDART® kits for EVOQ-DART TQ⁺ systems. These kits offer higher throughput for multiplex assays, a 95% reduction in solvent use, lower costs, and increased laboratory productivity, setting new standards for TDM and drugs of abuse screening.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.